Fausto Petrelli

Summary

Country: Italy

Publications

  1. doi request reprint The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis
    Fausto Petrelli
    Division of Medical Oncology, Department of Medical Oncology, Azienda Ospedaliera Treviglio, Piazzale Ospedale 1, 24047, Treviglio, BG, Italy
    Breast Cancer Res Treat 144:223-32. 2014
  2. doi request reprint Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis
    Fausto Petrelli
    Oncology Department, Medical Oncology Unit, Azienda Ospedaliera Treviglio, Treviglio BG, Italy Electronic address
    Eur Urol 65:350-7. 2014
  3. doi request reprint Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials
    Fausto Petrelli
    Medical Oncology Unit, Oncology Department, Azienda Ospedaliera Treviglio, Piazzale Ospedale 1, 24047, Treviglio, BG, Italy
    Med Oncol 31:776. 2014
  4. ncbi request reprint Cetuximab/irinotecan-chemotherapy in KRAS wild-type pretreated metastatic colorectal cancer: a pooled analysis and review of literature
    Sandro Barni
    Medical Oncology Unit, Oncology Department, Azienda Ospedaliera Treviglio Caravaggio, Piazzale Ospedale 1, 24047 Treviglio BG, Italia
    Rev Recent Clin Trials 8:101-9. 2013
  5. doi request reprint Surrogate end points and postprogression survival in renal cell carcinoma: an analysis of first-line trials with targeted therapies
    Fausto Petrelli
    Oncology Department, Medical Oncology Unit, Azienda Ospedaliera Treviglio, Treviglio, Italy Electronic address
    Clin Genitourin Cancer 11:385-9. 2013
  6. doi request reprint Response to neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast: a meta-analysis of published trials including 1,764 lobular breast cancer
    Fausto Petrelli
    Division of Medical Oncology, Department of Medical Oncology, Azienda Ospedaliera Treviglio, Piazzale Ospedale 1, 24047, Treviglio, BG, Italy
    Breast Cancer Res Treat 142:227-35. 2013
  7. doi request reprint Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer
    Fausto Petrelli
    UO Oncologia, Azienda Ospedaliera Treviglio, Piazzale Ospedale 1, 24047, Treviglio, Bergamo, Italy
    Target Oncol 8:291-4. 2013
  8. doi request reprint The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials
    F Petrelli
    Oncology Unit, Azienda Ospedaliera Treviglio, UO Oncologia, Piazzale Ospedale 1, 24047, Treviglio, Bergamo, Italy
    Target Oncol 8:173-81. 2013
  9. doi request reprint FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials
    Fausto Petrelli
    Medical Oncology Unit, Oncology Department, Azienda Ospedaliera Treviglio, Treviglio BG, Italy
    Clin Colorectal Cancer 12:145-51. 2013
  10. doi request reprint Platinum rechallenge in patients with advanced NSCLC: a pooled analysis
    Fausto Petrelli
    Azienda Ospedaliera di Treviglio, Oncology Department, Medical Oncology Unit, Piazzale Ospedale 1, 24047 Treviglio, BG, Italy
    Lung Cancer 81:337-42. 2013

Collaborators

Detail Information

Publications49

  1. doi request reprint The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis
    Fausto Petrelli
    Division of Medical Oncology, Department of Medical Oncology, Azienda Ospedaliera Treviglio, Piazzale Ospedale 1, 24047, Treviglio, BG, Italy
    Breast Cancer Res Treat 144:223-32. 2014
    ..39-4.61; P < 0.0001). In conclusion, pCR rates increase significantly with the addition of cisplatin or carboplatin in TNBC compared with NAC containing no platinum drugs. TN status is a predictor of benefit from platinum-based NAC. ..
  2. doi request reprint Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis
    Fausto Petrelli
    Oncology Department, Medical Oncology Unit, Azienda Ospedaliera Treviglio, Treviglio BG, Italy Electronic address
    Eur Urol 65:350-7. 2014
    ..Neoadjuvant chemotherapy before radical cystectomy (RC) is the preferred initial option for muscle-invasive bladder cancer (BCa). As in rectal and breast cancer, pathologic downstaging is associated with increased overall survival (OS)...
  3. doi request reprint Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials
    Fausto Petrelli
    Medical Oncology Unit, Oncology Department, Azienda Ospedaliera Treviglio, Piazzale Ospedale 1, 24047, Treviglio, BG, Italy
    Med Oncol 31:776. 2014
    ..Further analyses at patient-level data are required to confirm the surrogacy of PFS for OS with new agents...
  4. ncbi request reprint Cetuximab/irinotecan-chemotherapy in KRAS wild-type pretreated metastatic colorectal cancer: a pooled analysis and review of literature
    Sandro Barni
    Medical Oncology Unit, Oncology Department, Azienda Ospedaliera Treviglio Caravaggio, Piazzale Ospedale 1, 24047 Treviglio BG, Italia
    Rev Recent Clin Trials 8:101-9. 2013
    ..Here, the efficacy of this combination in patients with the KRAS wild-type gene as second- or further-line therapy is reviewed and data are collected in a pooled analysis...
  5. doi request reprint Surrogate end points and postprogression survival in renal cell carcinoma: an analysis of first-line trials with targeted therapies
    Fausto Petrelli
    Oncology Department, Medical Oncology Unit, Azienda Ospedaliera Treviglio, Treviglio, Italy Electronic address
    Clin Genitourin Cancer 11:385-9. 2013
    ..Improvement in DCR is strongly associated with improvement in median OS. In this population, DCR may be an appropriate surrogate for OS...
  6. doi request reprint Response to neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast: a meta-analysis of published trials including 1,764 lobular breast cancer
    Fausto Petrelli
    Division of Medical Oncology, Department of Medical Oncology, Azienda Ospedaliera Treviglio, Piazzale Ospedale 1, 24047, Treviglio, BG, Italy
    Breast Cancer Res Treat 142:227-35. 2013
    ..00001) and rate of BCS (from 35.4 to 54.8 %; OR = 2.1, 95 % CI 1.8-2.45, P < 0.00001) compared to ILC. The overall pCR rates and BCS decreased in the ILCs compared with IDC when treated with neoadjuvant chemotherapy. ..
  7. doi request reprint Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer
    Fausto Petrelli
    UO Oncologia, Azienda Ospedaliera Treviglio, Piazzale Ospedale 1, 24047, Treviglio, Bergamo, Italy
    Target Oncol 8:291-4. 2013
    ..The use of i.p. catumaxomab for the treatment of malignant ascites due to breast cancer should be explored further in appropriate clinical studies and its possible systemic effects should also be further investigated...
  8. doi request reprint The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials
    F Petrelli
    Oncology Unit, Azienda Ospedaliera Treviglio, UO Oncologia, Piazzale Ospedale 1, 24047, Treviglio, Bergamo, Italy
    Target Oncol 8:173-81. 2013
    ..The hypothesis that, in patients who lack substantial skin toxicity, this treatment is not beneficial and requires early discontinuation deserves further study...
  9. doi request reprint FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials
    Fausto Petrelli
    Medical Oncology Unit, Oncology Department, Azienda Ospedaliera Treviglio, Treviglio BG, Italy
    Clin Colorectal Cancer 12:145-51. 2013
    ..This indication is confirmed by robust data about RR, PFS, and survival obtained, which this pooled analysis of 29 trials also found. FOLFIRI-B remains 1 of the referent combinations when bevacizumab is considered as first-line therapy...
  10. doi request reprint Platinum rechallenge in patients with advanced NSCLC: a pooled analysis
    Fausto Petrelli
    Azienda Ospedaliera di Treviglio, Oncology Department, Medical Oncology Unit, Piazzale Ospedale 1, 24047 Treviglio, BG, Italy
    Lung Cancer 81:337-42. 2013
    ..The potential usefulness of platinum-based doublets as rechallenge for second-line chemotherapy has not yet been established...
  11. doi request reprint Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials
    Fausto Petrelli
    Division of Medical Oncology, Department of Medical Oncology, Azienda Ospedaliera Treviglio, Piazzale Ospedale 1, 24047, Treviglio, BG, Italy
    Breast Cancer Res Treat 140:233-40. 2013
    ..This strategy should be considered in patients free of disease after 5 years of hormonal therapy. ..
  12. doi request reprint KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials
    Fausto Petrelli
    Medical Oncology Unit, Oncology Department, Azienda Ospedaliera Treviglio, Piazzale Ospedale 1, 24047 Treviglio BG, Italy
    Med Oncol 30:650. 2013
    ..92; P = 0.01). This pooled analysis of 12 published studies shows that KRAS wt status is a good prognostic factor for B-based chemotherapy. Also, KRAS wt CRC is associated with a better RR with B plus chemotherapy than mut counterpart. ..
  13. doi request reprint Non-cancer-related mortality after cisplatin-based adjuvant chemotherapy for non-small cell lung cancer: a study-level meta-analysis of 16 randomized trials
    Fausto Petrelli
    Medical Oncology Unit, Oncology Department, Azienda Ospedaliera Treviglio, Piazzale Ospedale 1, 24047 Treviglio, BG, Italy
    Med Oncol 30:641. 2013
    ..In this meta-analysis of RCTs in NSCLC, cisplatin-based adjuvant chemotherapy was associated with a 30 % increase in non-lung cancer-related mortality compared with local therapy alone. ..
  14. doi request reprint A pooled analysis of 2618 patients treated with trastuzumab beyond progression for advanced breast cancer
    Fausto Petrelli
    Azienda Ospedaliera di Treviglio, UO Oncologia Medica, Treviglio, Italia
    Clin Breast Cancer 13:81-7. 2013
    ..In HER2+ MBC, continuing trastuzumab (T) after the progression during a first-line T-based regimen, represents 1 of the possible strategies, even if few data from randomized trials exist in this setting...
  15. doi request reprint Biological agents alone or in combination as second-line therapy in advanced non-small-cell lung cancer: systematic review of randomized studies
    Fausto Petrelli
    Oncology Unit, Oncology Department, Piazzale Ospedale 1, 24047, Treviglio BG, Italy
    Expert Rev Anticancer Ther 12:1299-312. 2012
    ..In this review, the authors examine existing trials comparing targeted therapies with the standard of care as second-line therapy for advanced non-small-cell lung cancer...
  16. doi request reprint Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer
    F Petrelli
    Oncology Unit, Azienda Ospedaliera di Treviglio, Treviglio, Italy
    Ann Oncol 24:186-92. 2013
    ..We also evaluated surrogacy of PFS and OS...
  17. doi request reprint Surgery of primary tumors in stage IV breast cancer: an updated meta-analysis of published studies with meta-regression
    Fausto Petrelli
    Medical Oncology Unit, Oncology Department, Azienda Ospedaliera Treviglio Caravaggio, Piazzale Ospedale 1, 24047, Treviglio, BG, Italy
    Med Oncol 29:3282-90. 2012
    ..Surgery of the primary tumor in stage IV breast cancer seems to offer a survival benefit in metastatic patients, in particular when it is offered in a multimodality treatment program...
  18. doi request reprint Anti-EGFR-targeting agents in recurrent or metastatic head and neck carcinoma: a meta-analysis
    Fausto Petrelli
    Oncology Unit, Azienda Ospedaliera Treviglio Caravaggio, Treviglio, Italy
    Head Neck 34:1657-64. 2012
    ..Anti-epidermal growth factor receptor (EGFR) therapies are effective in head and neck carcinoma. A meta-analysis was performed to assess their efficacy and safety in advanced head and neck carcinoma...
  19. doi request reprint Role of HER2-neu as a prognostic factor for survival and relapse in pT1a-bN0M0 breast cancer: a systematic review of the literature with a pooled-analysis
    F Petrelli
    Medical Oncology Unit, Oncology Department, Azienda Ospedaliera Treviglio Caravaggio, Piazzale Ospedale 1, 24047, Treviglio, BG, Italy
    Med Oncol 29:2586-93. 2012
    ..0006), but these data were presented in few studies. HER2+ pT1a-bN0M0 BC is associated with a dismal prognosis. In these patients, HER2 has to be taken into account when deciding on adjuvant therapy, and trastuzumab should be considered...
  20. doi request reprint Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials
    Fausto Petrelli
    Azienda Ospedaliera di Treviglio, Piazzale Ospedale 1, 24047, Treviglio BG, Italy
    Lung Cancer 78:8-15. 2012
    ..The objective of this review was to assess the predictive value of skin rash for outcome in patients with NSCLC treated with erlotinib and gefitinib...
  21. doi request reprint Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials
    F Petrelli
    Medical Oncology Unit, Oncology Department, Azienda Ospedaliera Treviglio Caravaggio, Treviglio, Italy
    Ann Oncol 23:1672-9. 2012
    ..Arterial and venous thromboembolic events (ATEs and VTEs excluding catheter-related events) were not investigated with these agents, and the risk of these events is still unknown...
  22. doi request reprint Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysis
    Fausto Petrelli
    Department of Medical and Surgical Oncology, Division of Medical Oncology, Azienda Ospedaliera Treviglio Caravaggio, Treviglio, BG, Italy
    Breast Cancer Res Treat 135:335-46. 2012
    ..However, sequential A + T schedules are associated with less toxicity, but a significant increase in non-breast cancer-related mortality compared with control arms with a greater dose of A...
  23. doi request reprint Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis
    F Petrelli
    Medical Oncology Unit, Oncology Department, Azienda Ospedaliera Treviglio Caravaggio, Piazzale Ospedale 1, 24047 Treviglio, BG, Italy
    Int J Colorectal Dis 27:997-1004. 2012
    ..We performed a meta-analysis of randomised controlled trials (RCTs) to assess their effect on overall response rate (ORR), the rate of radical resection (R0) and survival in patients with liver-limited initially unresectable mCRC...
  24. doi request reprint 5-Fluorouracil or capecitabine in the treatment of advanced colorectal cancer: a pooled-analysis of randomized trials
    Fausto Petrelli
    Azienda Ospedaliera Treviglio Caravaggio, Treviglio, BG, Italy
    Med Oncol 29:1020-9. 2012
    ..Only hand and foot syndrome is worse with C than with 5-FU. Activity and efficacy are similar. Capecitabine could be therefore considered standard of care in advanced CRC...
  25. doi request reprint Meta-analysis of concomitant compared to sequential adjuvant trastuzumab in breast cancer: the sooner the better
    Fausto Petrelli
    Azienda Ospedaliera Treviglio Caravaggio, Treviglio, BG, Italy
    Med Oncol 29:503-10. 2012
    ....
  26. doi request reprint Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials
    Fausto Petrelli
    Azienda Ospedaliera Treviglio Caravaggio, Unita Operativa di Oncologia, Treviglio BG, Italy
    Clin Lung Cancer 13:107-14. 2012
    ..All patients affected by NSCLC with an EGFR-positive mutation test result must be offered the opportunity to be treated with an EGFR TKI upfront or during the natural course of the disease if not previously exposed...
  27. doi request reprint Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies
    Fausto Petrelli
    Medical Oncology Unit, Azienda Ospedaliera Treviglio Caravaggio, Treviglio BG, Piazzale Ospedale 1, 24047, Treviglio BG, Italy
    Expert Opin Drug Saf 11:S9-19. 2012
    ..The purpose of our meta-analysis is to evaluate the frequency and the relative risk of hypomagnesemia in patients treated with cetuximab or panitumumab in randomized trials...
  28. doi request reprint A rare case of metastatic pancreatic hepatoid carcinoma treated with sorafenib
    Fausto Petrelli
    Medical Oncology Unit, Treviglio Caravaggio Hospital, Piazzale Ospedale 1, 24047 Treviglio, Bergamo, Italy
    J Gastrointest Cancer 43:97-102. 2012
    ..Diagnosis is challenging: alpha-Fetoprotein, the most useful marker, is not always positive...
  29. doi request reprint Bevacizumab in advanced breast cancer: an opportunity as second-line therapy?
    Fausto Petrelli
    Azienda Ospedaliera Treviglio Caravaggio, Treviglio, BG, Italy
    Med Oncol 29:1-4. 2012
    ....
  30. doi request reprint Progression of intramedullary metastasis during perioperative cessation of sunitinib
    Fausto Petrelli
    Department of Oncology, Azienda Ospedaliera Treviglio Caravaggio, Piazzale Ospedale 1, 12 24047 Treviglio, Bergamo, Italy
    Nat Rev Urol 7:634-7. 2010
    ..After 6 months, her extracranial lesions remained stable and the intramedullary lesion was undetectable on MRI...
  31. ncbi request reprint What else in gemcitabine-pretreated advanced pancreatic cancer? An update of second line therapies
    Fausto Petrelli
    Azienda Ospedaliera Treviglio Caravaggio, Treviglio BG, Italy
    Rev Recent Clin Trials 5:43-56. 2010
    ..At present, even though no data on benefits in unfit patients (Karnofsky < 70) are available, a fluopyrimidine agent still remains a reasonable treatment option...
  32. doi request reprint Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debate
    Fausto Petrelli
    Oncology Unit, Treviglio Hospital, Treviglio BG, Italy
    Med Oncol 28:401-8. 2011
    ....
  33. doi request reprint Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel
    Fausto Petrelli
    Oncology Unit, Azienda Ospedaliera Treviglio Caravaggio, Piazzale Ospedale 1, Treviglio BG, Italy
    Expert Opin Pharmacother 11:1413-32. 2010
    ..Nanoparticle albumin-bound paclitaxel (nab-P) is a CrEL-free formulation of paclitaxel. The human albumin-stabilized paclitaxel particles have a size of approximately 130 nm, which allows intravenous infusion without capillary blockage...
  34. doi request reprint Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials
    Fausto Petrelli
    Oncology Unit, Azienda Ospedaliera Treviglio Caravaggio, Piazzale Ospedale 1, 24047, Treviglio, BG, Italy
    J Cancer Res Clin Oncol 138:179-87. 2012
    ..Iron supplementation could improve the hematopoietic response of erythropoiesis-stimulating agents (ESAs) used for chemotherapy-induced anemia...
  35. doi request reprint Is there a role for maintenance therapy in non-small-cell lung cancer? An emerging issue
    Fausto Petrelli
    Azienda Ospedaliera Treviglio Caravaggio, Treviglio, BG, Italy
    Expert Rev Anticancer Ther 9:1455-65. 2009
    ....
  36. doi request reprint Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based?
    Fausto Petrelli
    Treviglio Hospital, Oncology Unit, Piazzale Ospedale 1, 24047 Treviglio BG, Italy
    Expert Opin Investig Drugs 18:1467-77. 2009
    ..Currently, treatment of TN BC is more empirical than evidence-based. The cornerstone of treatment is chemotherapy, but in the near future, novel target agents will emerge as possible partners...
  37. ncbi request reprint Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: a pooled analysis of two randomized trials
    Fausto Petrelli
    Azienda Ospedaliera Treviglio Caravaggio, Treviglio, Italy
    Anticancer Drugs 22:128-35. 2011
    ..Trastuzumab significantly reduces the risk of relapse and does not increase the risk of cardiotoxicity,despite being associated with anthracyclines. The largest benefit was observed in a locally advanced patient study...
  38. doi request reprint Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis
    Fausto Petrelli
    Azienda Ospedaliera Treviglio Caravaggio, Treviglio BG, Italy
    Int J Colorectal Dis 26:823-33. 2011
    ..The purpose of our meta-analysis is to evaluate the real effects of C and P in KRAS wild-type patients treated in randomized trials...
  39. doi request reprint A patient presenting nasal septum perforation during bevacizumab-containing chemotherapy for advanced breast cancer
    Fausto Petrelli
    Oncology Unit, Azienda Ospedaliera Treviglio Caravaggio, Piazzale Ospedale 1, 24047, Treviglio BG, Italy
    Breast Cancer 18:226-30. 2011
    ....
  40. doi request reprint Targeted therapies for the treatment of breast cancer in the post-trastuzumab era
    Fausto Petrelli
    Division of Medical Oncology, Azienda Ospedaliera Treviglio Caravaggio Hospital, Treviglio BG, Italy
    Oncologist 13:373-81. 2008
    ....
  41. doi request reprint Tamoxifen added to radiotherapy and surgery for the treatment of ductal carcinoma in situ of the breast: a meta-analysis of 2 randomized trials
    Fausto Petrelli
    Azienda Ospedaliera Treviglio Caravaggio, BG, Italy
    Radiother Oncol 100:195-9. 2011
    ..The purpose of our meta-analysis is to evaluate the reduction in recurrence (in situ or invasive) with the addition of tamoxifen (T), in particular in patients with DCIS treated with surgery+RT...
  42. ncbi request reprint Targeted therapies and other agents as first-line maintenance and beyond: particular benefit in pulmonary adenocarcinoma patients
    F Petrelli
    Azienda Ospedaliera Treviglio Caravaggio, Treviglio BG, Itlay
    Curr Med Chem 18:1640-50. 2011
    ..This article reviews the main studies on molecular targeted therapies in various lines of treatment of advanced lung adenocarcinoma...
  43. doi request reprint The emerging issue of ratio of metastatic to resected lymph nodes in gastrointestinal cancers: an overview of literature
    F Petrelli
    Azienda Ospedaliera Treviglio Caravaggio Treviglio BG, Italy
    Eur J Surg Oncol 37:836-47. 2011
    ..In conclusion, lymph node ratio stands out as an independent prognostic factor in adequately (nodal)-staged gastrointestinal epithelial malignancies and could be useful as a stratification factor in future randomised controlled trials...
  44. doi request reprint Erlotinib as maintenance therapy in patients with advanced non-small cell lung cancer: a pooled analysis of three randomized trials
    Fausto Petrelli
    Department of Medical Oncology, Azienda Ospedaliera Treviglio Caravaggio, Bergamo, Italy
    Anticancer Drugs 22:1010-9. 2011
    ..The benefit does not seem to be limited to a particular subgroup, although it is more pronounced in never-smoking women patients with nonsquamous carriers with a PS of 0...
  45. doi request reprint FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials
    Giordano Domenico Beretta
    Medical Oncology Unit, Humanitas Gavazzeni, Bergamo, Italy
    Med Oncol 30:486. 2013
    ..3 and 17.2 months. FOLFIRI-B is a reasonable and effective option for stage IV CRC pretreated with oxaliplatin and not exposed to B during first-line treatment. Its activity seems better than historical FOLFIRI-based second-line trials...
  46. pmc The risk for anemia with targeted therapies for solid tumors
    Sandro Barni
    Oncology Department, Medical Oncology Unit, Azienda Ospedaliera Treviglio, Italy
    Oncologist 17:715-24. 2012
    ..Anemia is a common manifestation in patients with cancer. Little is known about the frequency of and risk for anemia with targeted therapies used to treat solid tumors...
  47. pmc Cisplatin or not in advanced gastric cancer: a systematic review and meta-analysis
    Fausto Petrelli
    Medical Oncology Unit, Oncology Department, Azienda Ospedaliera Treviglio, Treviglio BG, Italy
    PLoS ONE 8:e83022. 2013
    ..The purpose of this meta-analysis study was to compare the efficacy of chemotherapy with and without cisplatin in patients with advanced GC...
  48. doi request reprint Benefit of adjuvant chemotherapy in elderly ER-negative breast cancer patients: benefits and pitfalls
    Sandro Barni
    Oncology Unit, Treviglio Hospital, Piazzale Ospedale 1, 24047, Treviglio BG, Italy
    Expert Rev Anticancer Ther 10:185-98. 2010
    ..Fit elderly patients with more aggressive forms (node-positive and ER-poor disease) seem to obtain the same benefits as younger patients, and thus have to be treated in the same manner...
  49. pmc Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study
    Sandro Barni
    Oncology Department, San Filippo Neri Hospital, Via Martinotti 20, Rome, 00135, Italy
    J Transl Med 9:179. 2011
    ..The aims of this retrospective analysis were to evaluate the thromboembolic risk and the benefit of thromboprophylaxis according to type of chemotherapy...